ArticleRheumatology advances in practice2026
Pregnancy outcomes in patients with axial spondyloarthritis: a UK-based survey.
Article in Rheumatology advances in practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore pregnancy outcomes in patients with axial spondyloarthritis (axSpA) in the UK. Methods: A patient-reported online survey, based on the EULAR core dataset for pregnancy registries in rheumatology, was conducted via the REDCap platform with data included between October 2022 and October 2023. Data were analysed descriptively. Results: A total of 139 pregnancies from 89 women following a diagnosis of axSpA were analysed. The mean age at pregnancy was 32.1 years (s.d. 4.3), at diagnosis was 27.6 years (s.d. 5.1) and at symptom onset was 20.8 years (s.d. 5.8). Most pregnancies were planned (90.6%) and achieved by natural conception (90.2%), with 68.3% conceiving within 1 year. Assisted conception was reported infrequently. Pre-pregnancy concerns such as pain levels increasing (74.8%), birth complications (62.6%) and passing on axSpA to a child (63.3%) were frequently reported. Flares occurred during 33.6% of pregnancies and in more than half (55.6%) during postpartum. The live birth rate was 76.4%. Rates of pre-eclampsia and congenital anomalies were 5.4% and 9.5%, respectively. Caesarean section occurred in 53.8% of pregnancies, with active disease and patient choice being core reasons. Most infants received vaccinations as scheduled (83.5%). AxSpA did not affect the decision to breastfeed for 82.5% of pregnancies, but it did affect perceived ability to care for the baby in the first 6 months (61.3%). Conclusion: Many women with axSpA experience increased time to pregnancy, disease-related pre-pregnancy worries, flares and delivery via caesarean section. Pre-pregnancy counselling may be important for women of reproductive age with axSpA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.